The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance
Open accessAbstract
The rapid evolution and dissemination of antibiotic resistance among bacterial pathogens are outpacing the development of new antibiotics, but antivirulence agents provide an alternative. These agents can circumvent antibiotic resistance by disarming pathogens of virulence factors that facilitate human disease while leaving bacterial growth pathways — the target of traditional antibiotics — intact. Either as stand-alone medications or together with antibiotics, these drugs are intended to treat bacterial infections in a largely pathogen-specific manner. Notably, development of antivirulence drugs requires an in-depth understanding of the roles that diverse virulence factors have in disease processes. In this Review, we outline the theory behind antivirulence strategies and provide examples of bacterial features that can be targeted by antivirulence approaches. Furthermore, we discuss the recent successes and failures of this paradigm, and new developments that are in the pipeline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Origins and evolution of antibiotic resistance
Davies, J., & Davies, D. (2010) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00016-10 · Cited by 5,784
Kaper, J. B., Nataro, J. P., & Mobley, H. L. T. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro818 · Cited by 5,583
Liu, Y.-Y., Wang, Y., Walsh, T. R., Yi, L.-X., Zhang, R., Spencer, J., Doi, Y., Tian, G., Dong, B., Huang, X., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00424-7 · Cited by 5,398
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Urinary tract infections: epidemiology, mechanisms of infection and treatment options
Flores-Mireles, A. L., Walker, J. N., Caparon, M., & Hultgren, S. J. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3432 · Cited by 4,213
QUORUM SENSING: Cell-to-Cell Communication in Bacteria
Waters, C. M., & Bassler, B. L. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.012704.131001 · Cited by 3,979
Hidron, A. I., Edwards, J. R., Patel, J., Horan, T. C., Sievert, D. M., Pollock, D. A., Fridkin, S. K., & National Healthcare Safety Network Team and Participating National Healthcare Safety Network Facilities (2008) · Infection Control & Hospital Epidemiology · doi:10.1086/591861 · Cited by 3,724
The human microbiome: at the interface of health and disease
Cho, I., & Blaser, M. J. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3182 · Cited by 3,449
Antibiotic resistance is ancient
D’Costa, V. M., King, C. E., Kalan, L., Morar, M., Sung, W. W. L., Schwarz, C., Froese, D., Zazula, G., Calmels, F., Debruyne, R., et al. (2011) · Nature · doi:10.1038/nature10388 · Cited by 2,720
Burden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641
Cited by
Natural products in drug discovery: advances and opportunities
Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., Taskforce, T. I. N. P. S., Orhan, I. E., Banach, M., Rollinger, J. M., Barreca, D., Weckwerth, W., Bauer, R., et al. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00114-z · Cited by 5,392
Antimicrobial Resistance: A Growing Serious Threat for Global Public Health
Salam, M. A., Al-Amin, M. Y., Salam, M. T., Pawar, J. S., Akhter, N., Rabaan, A. A., & Alqumber, M. A. A. (2023) · Healthcare · doi:10.3390/healthcare11131946 · Cited by 2,338
Pathogenicity and virulence of Staphylococcus aureus
Cheung, G. Y. C., Bae, J. S., & Otto, M. (2021) · Virulence · doi:10.1080/21505594.2021.1878688 · Cited by 1,380
Self-citationHorcajada, J. P., Montero, M., Oliver, A., Sorlí, L., Luque, S., Gómez-Zorrilla, S., Benito, N., & Grau, S. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00031-19 · Cited by 961
The global preclinical antibacterial pipeline
Theuretzbacher, U., Outterson, K., Engel, A., & Karlén, A. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0288-0 · Cited by 738
Pathogen elimination by probiotic Bacillus via signalling interference
Piewngam, P., Zheng, Y., Nguyen, T. H., Dickey, S. W., Joo, H.-S., Villaruz, A. E., Glose, K. A., Fisher, E. L., Hunt, R. L., Li, B., et al. (2018) · Nature · doi:10.1038/s41586-018-0616-y · Cited by 644
Self-citationAntibiotic Resistance and the MRSA Problem
Vestergaard, M., Frees, D., & Ingmer, H. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0057-2018 · Cited by 490
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 490
Application of Light Scattering Techniques to Nanoparticle Characterization and Development
Carvalho, P. M., Felício, M. R., Santos, N. C., Gonçalves, S., & Domingues, M. M. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00237 · Cited by 402
Otto, M. (2018) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0023-2018 · Cited by 381
Self-citationBiomimetic Nanotechnology toward Personalized Vaccines
Zhou, J., Kroll, A. V., Holay, M., Fang, R. H., & Zhang, L. (2020) · Advanced Materials · doi:10.1002/adma.201901255 · Cited by 328
Multidrug-resistant Gram-negative bacterial infections
Macesic, N., Uhlemann, A.-C., & Peleg, A. Y. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02081-6 · Cited by 315
Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections
Ma, Y., Wang, C., Li, Y., Li, J., Wan, Q., Chen, J., Tay, F. R., & Niu, L. (2020) · Advanced Science · doi:10.1002/advs.201901872 · Cited by 314
A single-cell nanocoating of probiotics for enhanced amelioration of antibiotic-associated diarrhea
Pan, J., Gong, G., Wang, Q., Shang, J., He, Y., Catania, C., Birnbaum, D., Li, Y., Jia, Z., Zhang, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29672-z · Cited by 309
Liao, C., Huang, X., Wang, Q., Yao, D., & Lu, W. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.926758 · Cited by 309
Fleitas Martínez, O., Cardoso, M. H., Ribeiro, S. M., & Franco, O. L. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00074 · Cited by 304
“In addition to disrupting the production and assembly of virulence factors; anti-virulence drugs have also been focused on interfering with the virulence factor functions (Mühlen and Dersch, 2016; Dickey et al., 2017).”
BackgroundAntibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?
Domalaon, R., Idowu, T., Zhanel, G. G., & Schweizer, F. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00077-17 · Cited by 285
Emerging and evolving concepts in gene essentiality
Rancati, G., Moffat, J., Typas, A., & Pavelka, N. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.74 · Cited by 277
Annunziato, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235844 · Cited by 256
Liang, X., Chen, D., Wang, J., Liao, B., Shen, J., Ye, X., Wang, Z., Zhu, C., Gou, L., Zhou, X., et al. (2023) · International Journal of Oral Science · doi:10.1038/s41368-023-00245-0 · Cited by 32
Mutalik, V. K., & Arkin, A. P. (2022) · iScience · doi:10.1016/j.isci.2022.104121 · Cited by 32
Hossain, S., Veri, A. O., & Cowen, L. E. (2020) · mBio · doi:10.1128/mbio.00290-20 · Cited by 31
Kundracik, E., Trichka, J., Díaz Aponte, J., Roistacher, A., & Rietsch, A. (2022) · mBio · doi:10.1128/mbio.02381-22 · Cited by 18
Metadata
- Authors
- Dickey, S. W., Cheung, G. Y. C., & Otto, M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2017-03-24
- Volume
- 16
- Issue
- 7
- Pages
- 457-471
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2598898392
- Cited by
- 799
- References
- 163
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.